| Literature DB >> 35745176 |
Mari Maeda-Yamamoto1, Osamu Honmou2, Masanori Sasaki2, Akane Haseda3, Hiroyo Kagami-Katsuyama3, Toshihiko Shoji1, Ai Namioka2, Takahiro Namioka2, Hirotoshi Magota2, Shinichi Oka2, Yuko Kataoka-Sasaki2, Ryou Ukai2, Mitsuhiro Takemura2, Jun Nishihira3.
Abstract
The purple-flesh potato (Solanum tuberosum L.) cultivar "Shadow Queen" (SQ) naturally contains anthocyanins. This randomized, double-blind, placebo-controlled study determines whether ingesting purple potatoes increases the number of mesenchymal stem cells (MSC) and improves stress response, a minor health complaint in healthy adults (registration number: UMIN000038876). A total of 15 healthy subjects (ages: 50-70 years) with minor health complaints were randomly assigned to one of two groups. For 8 weeks, the placebo group received placebo potatoes cv. "Haruka" and the test group received test potato cv. SQ containing 45 mg anthocyanin. The MSC count and several stress responses were analyzed at weeks 0 and 8 of the intake periods. The ingestion of a SQ potato did not affect the MSC count but markedly improved psychological stress response, irritability, and depression as minor health complaints compared with "Haruka". No adverse effects were noted. Hence, an 8-week intake of SQ could improve stress responses.Entities:
Keywords: anthocyanins; improvement of minor health complaints; purple-fresh potato cv. “Shadow Queen”; reducing the effect of the stress response; the brief job stress questionnaire
Mesh:
Substances:
Year: 2022 PMID: 35745176 PMCID: PMC9227939 DOI: 10.3390/nu14122446
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Schematic representation of the study/protocol.
Nutritional and functional components in test potatoes (75 g/day).
| Placebo (“Haruka”) | Test (“Shadow Queen”) | |
|---|---|---|
| Anthocyanins as delphinidin equivalents (mg) | 0.0 | 45.0 |
| Water (g) | 60.2 | 58.4 |
| Protein (g) | 1.5 | 1.6 |
| Fat (g) | 0.15 | 0.15 |
| Ash (g) | 0.7 | 0.8 |
| Carbohydrate (g) | 12.5 | 14.1 |
| Dietary fiber (g) | 1.3 | 1.2 |
| Energy (kcal) | 55 kcal | 62 kcal |
| NaCl (mg) | 0.0 | 2.1 |
NaCl, sodium chloride.
Baseline characteristics of subjects in the test (“Shadow Queen”) and placebo (“Haruka”) groups.
| Baseline Characteristics | Placebo (“Haruka“) | “Shadow Queen” | |
|---|---|---|---|
| Gender (male/female) ( | 8 (2/6) | 7 (2/5) | |
| Age (years) | 56.1 ± 4.4 | 55.1 ± 3.8 | 0.653 |
| Body weight (kg) | 54.9 ± 10.3 | 50.9 ± 6.3 | 0.390 |
| Body mass index (kg/m2) | 22.6 ± 5.6 | 20.8 ± 2.2 | 0.199 |
| Body fat ratio (%) | 29.1 ± 5.6 | 25.3 ± 9.3 | 0.355 |
| VAS questionnaires (mm) | 196.1 ± 93.4 | 222.0 ± 97.6 | 0.610 |
| Intake rate (%) | 100.0 ± 0 | 98.7 ± 2.7 | 0.379 |
Values are shown as mean ± standard deviations. n, number of subjects; VAS (visual analog scale) questionnaires = mean of the sum of four VAS questionnaires (eye fatigue, eye pain, irritability, and awareness of stress). p values were determined by Student’s t-test for independent samples vs. placebo “Haruka”.
Figure 2Study flowchart (n = total participants, male/female).
Figure 3Change in the mesenchymal stem cells (MSC) count. The horizontal line in the boxplot represents the median, and the × mark represents the mean.
Changes in stress response scores as a secondary outcome after taking “Shadow Queen” and “Haruka”.
| Stress Response (Score) | Intervention | Week 0 | Week 8 | Week 0 vs. Week 8 | Changes in Placebo vs. Test Food |
|---|---|---|---|---|---|
| Psychological stress response | “Haruka” | 4.35 ± 3.77 | 4.75 ± 4.20 | 0.381 | 0.007 ** |
| (0–18) | “Shadow Queen” | 6.57 ± 4.35 | 3.14 ± 3.34 | 0.026# | |
| Physical stress response (0–11) | “Haruka” | 2.50 ± 2.51 | 1.88 ± 2.59 | 0.370 | 0.794 |
| “Shadow Queen” | 1.71 ± 2.43 | 0.86 ± 1.21 | 0.172 | ||
| Vigor (3–12) | “Haruka” | 5.88 ± 2.59 | 6.00 ± 2.14 | 0.802 | 0.367 |
| “Shadow Queen” | 6.00 ± 2.16 | 6.86 ± 3.02 | 0.225 | ||
| Irritability (3–12) | “Haruka” | 6.25 ± 1.04 | 6.00 ± 1.31 | 0.563 | 0.028 * |
| “Shadow Queen” | 7.00 ± 2.77 | 5.14 ± 2.34 | 0.011 # | ||
| Fatigue (3–12) | “Haruka” | 6.25 ± 2.60 | 5.13 ± 3.04 | 0.065 | 0.583 |
| “Shadow Queen” | 7.14 ± 2.67 | 5.57 ± 2.82 | 0.042 # | ||
| Anxiety (3–12) | “Haruka” | 5.13 ± 1.46 | 5.50 ± 2.62 | 0.634 | 0.146 |
| “Shadow Queen” | 6.00 ± 1.63 | 4.86 ± 1.07 | 0.103 | ||
| Depression (6–24) | “Haruka” | 9.38 ± 4.03 | 10.00 ± 4.24 | 0.217 | 0.009 ** |
| “Shadow Queen” | 10.86 ± 2.73 | 8.86 ± 1.57 | 0.038 # | ||
| Physical Complaints (11–44) | “Haruka” | 19.63 ± 6.21 | 18.38 ± 7.67 | 0.454 | 0.519 |
| “Shadow Queen” | 19.43 ± 6.02 | 16.86 ± 3.80 | 0.063 |
The brief job-stress questionnaire was used to examine stress responses. Values are shown as the means ± standard deviation. Student’s t-test for independent samples vs. placebo, paired t-test vs. 0 weeks was performed to analyze the values. Statistical significance, *; <0.05, **; <0.01 vs. placebo, #; <0.05 vs. 0 weeks.
Figure 4The changes in the brief job-stress questionnaire from week 0 to week 8. (A) Changes in the psychological stress response; (B) changes in irritability; and (C) changes in depression. Statistical significance: * p < 0.05; ** p < 0.01 vs. placebo group.
Changes in the visual analog scale (VAS) on fatigue as a secondary outcome after taking “Haruka” or “Shadow Queen”.
| Visual Analog Scale | Intervention | Week 0 | Week 4 | Week 8 | ΔWeek 4 | ΔWeek 8 |
|---|---|---|---|---|---|---|
| Eyestrain (0–100) | “Haruka” | 35.38 ± 23.87 | 42.75 ± 30.58 | 45.50 ± 23.78 | 7.38 ± 24.70 | 10.13 ± 21.52 |
| “Shadow Queen” | 51.29 ± 32.63 | 67.86 ± 25.06 | 74.86 ± 22.66 | 16.57 ± 27.55 | 23.57 ± 29.22 | |
| - | - | - | 0.507 | 0.324 | ||
| Eye pain (0–100) | “Haruka” | 70.00 ± 30.74 | 68.75 ± 32.67 | 67.38 ± 29.90 | −1.25 ± 32.06 | −2.63 ± 21.32 |
| “Shadow Queen” | 76.14 ± 31.03 | 79.86 ± 26.12 | 86.14 ± 22.57 | 3.71 ± 29.64 | 10.00 ± 24.67 | |
| - | - | - | 0.762 | 0.307 | ||
| Irritability (0–100) | “Haruka” | 66.38 ± 25.14 | 52.00 ± 20.28 | 58.50 ± 23.31 | −14.38 ± 26.10 | −7.88 ± 23.39 |
| “Shadow Queen” | 65.43 ± 26.74 | 74.86 ± 28.35 | 73.00 ± 25.94 | 9.43 ± 27.16 | 7.57 ± 21.75 | |
| - | - | - | 0.107 | 0.210 | ||
| Stress (0–100) | “Haruka” | 48.00 ± 31.06 | 43.00 ± 28.06 | 39.50 ± 21.21 | −5.00 ± 23.10 | −8.50 ± 17.31 |
| “Shadow Queen” | 56.43 ± 30.99 | 72.29 ± 29.21 | 69.29 ± 22.76 | 69.29 ± 22.76 | 12.86 ± 22.39 | |
| - | - | - | 0.158 | 0.058 |
A VAS questionnaire on fatigue was used, with self-assessment of the worst (0) to best (100) status. Values are shown as the means ± standard deviation. Student’s t-test for independent samples vs. placebo, paired t-test vs. 0 weeks was performed to analyze the values. Δ, changes.
Changes in the secondary outcome after taking “Shadow Queen” and “Haruka”.
| Secondary Outcome | Intervention | Week 0 | Week 8 | Week 0 vs. Week 8 | Changes in Placebo vs. Test Food |
|---|---|---|---|---|---|
| Blood 1,5-anhydroglucitol(1,5-AG) | “Haruka” | 18.30 ± 7.93 | 19.61 ± 8.84 | 0.012 # | 0.017 * |
| (µg/mL) | “Shadow Queen” | 20.96 ± 3.97 | 20.54 ± 4.46 | 0.447 | |
| Urine 8-hydroxy-2’-deoxyguanisine | “Haruka” | 6.39 ± 1.59 | 5.28 ± 2.02 | 0.059 | 0.520 |
| (8-OHdG) (ng/mg/Creatinine correction value) | “Shadow Queen” | 7.33 ± 3.49 | 5.16 ± 2.93 | 0.194 |
Values are shown as the means ± standard deviation. Student’s t-test for independent samples vs. placebo, paired t-test vs. 0 weeks was performed to analyze the values. Statistical significance, *; <0.05 vs. placebo, #; <0.05 vs. 0 weeks.